GFLW - ETF AI Analysis
Top Page
VictoryShares Free Cash Flow Growth ETF (GFLW)
GFLW, the VictoryShares Free Cash Flow Growth ETF, earns a solid overall rating thanks to several strong, growth-focused holdings like Nvidia, Newmont Mining, Lam Research, and Applied Materials, which combine robust financial performance with positive earnings outlooks and strategic positioning in areas such as AI and advanced technologies. However, some holdings like SanDisk and Cardinal Health face valuation and profitability concerns, and the fund’s tilt toward a smaller set of tech and industrial names means investors should be aware of risks from potential overvaluation, high leverage, and sector-specific slowdowns.
GFLW vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.17B
- Region
- North America
- Expense Ratio
- 0.39%
- Beta
- 1.28
- Issuer
- VictoryShares
- Inception Date
- Dec 03, 2024
- Dividend Yield
- 0.36%
- Asset Class
- Equity
- Index Tracked
- Victory Free Cash Flow Growth Index
GFLW Summary
VictoryShares Free Cash Flow Growth ETF (GFLW) is a U.S. stock fund that follows the Victory Free Cash Flow Growth Index, focusing on large, established companies that are growing the cash they generate from their businesses. It holds well-known names like Nvidia and Eli Lilly, along with firms in technology, health care, and industrials, giving investors a mix of leading companies in different sectors. Someone might invest in GFLW to seek long-term growth from financially strong market leaders while staying diversified across industries. A key risk is that it is heavily tilted toward growth and tech-related stocks, so its price can rise and fall sharply with market swings.
How much will it cost me?
This ETF has an expense ratio of 0.39%, which means you’ll pay about $3.90 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because it’s actively managed, using a specific strategy to pick companies with strong free cash flow growth.
What would affect this ETF?
GFLW could benefit if the U.S. economy stays healthy, technology and health care companies keep innovating, and strong free cash flow remains a priority for large, well-known firms like Nvidia, Eli Lilly, and Caterpillar. On the downside, higher interest rates, slower economic growth, or tighter regulations on tech and health care could hurt these cash-generating businesses and weigh on the ETF’s future returns.
GFLW Top 10 Holdings
GFLW is leaning heavily into U.S. tech and health care, with a cast of cash‑rich leaders driving the story. Dell has been the surprise star, surging on AI momentum, while Eli Lilly and Cardinal Health keep the health care side steadily lifting the fund. Royalty Pharma adds a niche biotech royalty angle that’s quietly rising. On the other hand, chip names like Nvidia, Applied Materials, and Lam Research have seen more mixed, recently lagging action, occasionally tugging on returns even as the broader semiconductor theme remains central to the ETF’s positioning.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 4.44% | $51.77M | $1.33T | 67.86% | 72Outperform |
 NVDA | Nvidia | 3.30% | $38.49M | $4.93T | 0.86% | 76Outperform |
 CAT | Caterpillar | 2.68% | $31.25M | $286.26B | 6.79% | 76Outperform |
 DELL | Dell Technologies | 2.84% | $33.05M | $269.78B | 163.52% | 65Neutral |
 SNDK | SanDisk Corp | 2.70% | $31.40M | $166.34B | 487.73% | 55Neutral |
 CAH | Cardinal Health | 2.84% | $33.06M | $58.00B | 31.94% | 66Neutral |
 RPRX | Royalty Pharma | 2.80% | $32.64M | $38.72B | 81.86% | 79Outperform |
 NEM | Newmont Mining | 2.15% | $25.07M | $110.79B | 29.52% | 81Outperform |
 AMAT | Applied Materials | 2.09% | $24.39M | $309.57B | 67.74% | 77Outperform |
 LRCX | Lam Research | 1.95% | $22.69M | $298.69B | 48.51% | 77Outperform |
GFLW Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GFLW, the sentiment is Negative. The current price of 31.32 is below the 20-day moving average (MA) of 32.94, below the 50-day MA of 33.31, and above the 200-day MA of 30.84, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 34.60 is Neutral, neither overbought nor oversold. The STOCH value of 49.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GFLW.
GFLW Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GFLW | $31.32 | $37.00(18.14% Upside) | $1.17B | 0.39% | 72Outperform |
 JGRO | $91.05 | $123.53(35.67% Upside) | $9.76B | 0.44% | 73Outperform |
 CNEQ | $37.14 | $55.36(49.06% Upside) | $7.82B | 0.56% | 68Neutral |
 FELG | $42.23 | $58.31(38.07% Upside) | $5.69B | 0.18% | 75Outperform |
 QGRW | $64.56 | $89.58(38.76% Upside) | $3.22B | 0.28% | 75Outperform |
 NULG | $107.16 | $144.43(34.78% Upside) | $3.01B | 0.26% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GFLW | VictoryShares Free Cash Flow Growth ETF | 31.32 | 2.14 | 7.35% | |
| JGRO | JPMorgan Active Growth ETF | 91.05 | -5.28 | -5.48% | |
| CNEQ | Alger Concentrated Equity ETF | 37.14 | 1.09 | 3.02% | |
| FELG | Fidelity Enhanced Large Cap Growth ETF | 42.23 | -0.39 | -0.92% | |
| QGRW | WisdomTree U.S. Quality Growth Fund | 64.56 | 4.19 | 6.94% | |
| NULG | Nuveen ESG Large-Cap Growth ETF | 107.16 | 5.14 | 5.04% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.